Patient enrollment has been completed in two phase 3 trials of faricimab for wet age-related macular degeneration, according to communication from Genentech.
The TENAYA and LUCERNE trials, as well as the phase 3 YOSEMITE and RHINE trials, which are studying the drug in patients with diabetic macular edema, are now fully recruited with more than 3,000 patients.
Faricimab, a bispecific antibody that simultaneously binds to and neutralizes Angiopoietin-2 and VEGF-A, is being compared against Eylea (aflibercept, Regeneron) in the TENAYA and LUCERNE trials.
“Genentech remains committed to
Uncategorized